Long-Term Follow-up Protocol for Subjects Treated With JCAR015
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs JCAR 015 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Juno Therapeutics
- 09 Oct 2017 Planned End Date changed from 1 Dec 2036 to 1 Dec 2032.
- 09 Oct 2017 Planned primary completion date changed from 1 Dec 2036 to 1 Dec 2032.
- 01 Mar 2017 According to a Juno Therapeutics media release, the company has made a strategic decision to cease development of JCAR015.